Cited 0 times in
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이민영 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2021-12-28T16:52:45Z | - |
dc.date.available | 2021-12-28T16:52:45Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 2233-6079 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186832 | - |
dc.description.abstract | Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating peroxisome proliferator-activated receptor γ. Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to their potent glycemic efficacy and low risk of hypoglycemia. However, their use has decreased because of side effects and safety issues, such as cardiovascular concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation), a novel TZD, was developed to meet the demands for an effective and safe TZD. Lobeglitazone shows similar glycemic efficacy to pioglitazone, with a lower effective dose, and favorable safety results. It also showed pleiotropic effects in preclinical and clinical studies. In this article, we summarize the pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Diabetes Association | - |
dc.relation.isPartOf | DIABETES & METABOLISM JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Diabetes Mellitus, Type 2* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents / adverse effects | - |
dc.subject.MESH | Pyrimidines | - |
dc.subject.MESH | Thiazolidinediones* / adverse effects | - |
dc.title | Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jaehyun Bae | - |
dc.contributor.googleauthor | Taegyun Park | - |
dc.contributor.googleauthor | Hyeyoung Kim | - |
dc.contributor.googleauthor | Minyoung Lee | - |
dc.contributor.googleauthor | Bong-Soo Cha | - |
dc.identifier.doi | 10.4093/dmj.2020.0272 | - |
dc.contributor.localId | A05491 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J00720 | - |
dc.identifier.eissn | 2233-6087 | - |
dc.identifier.pmid | 33866775 | - |
dc.subject.keyword | Diabetes mellitus , type 2 | - |
dc.subject.keyword | Lobeglitazone | - |
dc.subject.keyword | Thiazolidinediones | - |
dc.contributor.alternativeName | Lee, Minyoung | - |
dc.contributor.affiliatedAuthor | 이민영 | - |
dc.contributor.affiliatedAuthor | 차봉수 | - |
dc.citation.volume | 45 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 326 | - |
dc.citation.endPage | 336 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM JOURNAL, Vol.45(3) : 326-336, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.